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Purpose: This study is aimed at achieving improvement in the efficacy, reduced toxicity and 
enhancement of therapeutic index of irinotecan.   
Methods: Proniosomes of irinotecan hydrochloride trihydrate were prepared by slurry method using 
different surfactants, cholesterol and dicetyl phosphate. The formulations were then characterized with 
respect to shape, surface morphology, entrapment efficiency, in vitro drug release, in vivo drug targeting 
and stability. 
Results: The proniosomes were smooth in texture indicating, thin and uniform coating over maltodextrin 
powder. The highest entrapment efficiency was found for formulation F2 (74.9 ± 2.7 %). The highest 
cumulative drug release in 24 h was achieved with formulation F3 (98.2 %) In vivo results for the 
proniosomes reveal that the drug was preferentially targeted to liver followed by lung and spleen.  
Stability studies indicate that 4 ºC was the most suitable condition for the storage of formulation F2.  
Conclusion: Proniosomes offer a suitable alternative colloidal carrier approach to achieving drug 
targeting. Proniosomes containing irinotecan are retained at targeted sites and are capable of releasing 
drug for an extended period of time.  
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INTRODUCTION 
 
Research in the field of drug delivery system, 
which continues to progress rapidly, aims at 
the development of drug delivery systems 
(DDS) with optimum therapeutic benefits 
including safe and effective management of 
disease [1]. 
 
The concept of drug delivery to a specific site 
for the treatment of localized disease in the 
body, thereby decreasing drug adverse 
effects and improving its therapeutic index, is 
often considered a challenge [2]. The idea of 
a drug carrier with targeted specificity has 
always fascinated scientists for decades and 
in the last decade, limited success have been 
achieved in this regard. One such approach 
involves the use of vesicular drug carrier that 
can provide site specificity combined with 
optimal drug release profile [3]. Amongst 
various carriers utilized for target-oriented 
drug delivery, vesicular drug delivery systems 
in the form of liposome and niosomes have 
been most extensively investigated. 
Liposomal formulations have the limitation of 
poor stability and low drug entrapment 
efficiency while niosomes exhibit physical 
instability, aggregation, fusion, and leakage 
of entrapped drug, thus limiting the shelf-life 
of the dispersion [4,5]. Proniosomes [6] 
circumvent all the inherent drawbacks of 
niosomes and they offer a versatile vesicle 
delivery concept with the potential for 
targeted drug delivery. They are dry 
formulations of surfactant-coated carrier 
which can be hydrated before their use to 
obtain a suspension of niosomes. The 
additional convenience of transportation, 
distribution, storage and dosing make 
proniosomes a promising industrial product 
[7].  
 
Irinotecan, chemically, is a synthetic 
analogue of the natural alkaloid, campto-
thecin. It is a chemotherapeutic agent, a 
topoisomerase 1 inhibitor and mainly used as 
a drug of choice in colon cancer [8]. The most 
significant adverse effects of irinotecan are 
severe diarrhea and extreme suppression of 
the immune systems. Irinotecan-associated 
diarrhea is severe and clinically significant, 
sometimes leading to severe dehydration 
requiring hospitalization. Also, the immune 
system is adversely impacted which is 
reflected in dramatically lowered white blood 
cell counts in blood [9]. Hence, the objective 
of the present work is to develop an 
alternative vesicular drug delivery system for 
irinotecan in the form of proniosomes which 
will have advantages of controlled drug 
release and site specificity, increased drug 
stability, high drug pay load and absence of 






Irinotecan hydrochloride trihydrate was 
obtained as a gift sample from M/S Cipla 
Limited, Bangalore, India  while maltodextrin 
was also received as a gift from Riddhi Siddhi 
Glucobials Ltd, Gokak, Karnataka, India. 
Surfactants, cholesterol and dicetyl 
phosphate were purchased from Loba Chem 
Pvt Ltd, Mumbai, India. All other reagents 




Healthy Albino Wistar rats of either sex 
weighing 200 – 250 g were selected for the 
study. The animals were housed under 
standard conditions and fed with standard 
pellet diet (Lipton India Ltd., Mumbai) and 
drinking water. The experimental protocol 
was approved by the Institutional Animal 
Ethics Committee of N.E.T. Pharmacy 
College Raichur, Karnataka, India (Reg no. 
576/02/bc/CPCSEA). The animals were 
handled as per Recommended Animal 
Handling, Guidelines and Audit Guide [11].  
 
Formulation of proniosomes  
 
Optimized proportions of Surfactants, 
cholesterol, and dicetylphosphate (molar ratio 
47.5:47.5:5, respectively), were used in this 
work [7]. A stock solution of surfactants in 
chloroform was prepared with 164 mmol/L 
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surfactant, 164 mmol/L cholesterol, and 17.2 
mmol/L dicetylphosphate. Proniosomes with 
maltodextrin as the carrier were prepared by 
a slurry method using surfactants like span 
20 (F1), span 60 (F2), tween 20 (F3) and 
tween 80(F4). 10 g of maltodextrin powder 
was added to a 250-mL round-bottom flask 
and the entire volume of surfactant mixture 
(14.5 mL) was added directly to the flask. The 
flask was attached to the rotary evaporator 
with the rotation speed set at 60 RPM and 
temperature to 37
0
c. Vacuum was applied 
until the powder appeared to be dry and free 
flowing. The flask was removed from the 
evaporator and the proniosomes were sealed 
in screw cap vials, until further use. 
 
Scanning electron microscopy (SEM) 
 
Particle shape analysis was done by SEM 
using JEOL JSM-T330A scanning 
microscope. Cleaned brass specimen studs 
were used for mounting the samples. Wet 
solvent paint was applied on these studs and 
while the paint was wet, the proniosome 
powder was placed on each stud and allowed 
to dry. Thereafter, photomicrographs were 
taken [12].  
 
Measurement of angle of repose 
 
The angle of repose of the dry proniosome 
powder was measured by the funnel method 
[13]. Briefly, the maltodextrin powder or 
proniosome powder was poured into a funnel 
which was fixed at a position so that the 
orifice of the funnel was 10 cm from the base. 
When the powder was poured into the funnel, 
it flowed down to form a cone on the flat 
surface. The height of the cone (h) and the 
radius (r) of its base were measured, and the 
angle of repose computed using Eq 1. 
 
         Ø = tan
-1
h/r  …………………… (1) 
 
Drug loading and rehydration of 
proniosomes 
 
Irinotecan hydrochloride trihydrate (10 mg) 
was dissolved in 10 ml of PBS (pH 7.4). The 
drug solution was added to a vial containing 
proniosome powder, the vial was capped, 
attached to a vortex mixer (Remi Equipment 
Pvt Ltd, Mumbai, India) and agitated at 
maximum speed for 2 min to yield niosomes. 
 
Determination of drug entrapment 
efficiency:  
 
The degree of incorporation of irinotecan 
hydrochloride trihydrate in the proniosomes 
(entrapment efficiency) was evaluated. 
Following centrifugation of the aqueous 
noisome suspension [14], amount of the free 
drug in the supernatant as well as the amount 
of the incorporated drug were determined 
spectrophotometrically model UV-1700, 
Shimadzu Corporation, Japan) at 369 nm. 
Entrapment efficiency (EE, %) was computed 
using Eq 2.  
         
EE (%) = 100 (Wo – Wf)/Wo ………… (2) 
 
where Wo is the total amount of drug used in 
preparing the proniosomes and Wf is the 
amount of free drug in the supernatant.  
 




Niosomes equivalent to 10 mg of irinotecan 
hydrochloride trihydrate were taken into a 
tube with one end of the tube closed with a 
dialysis membrane. The tube was palced 
vertically in a beaker containing 50 ml of PBS 
(pH 7.4) in such a way that it just touched the 
surface of the buffer solution. The whole set-
up was placed on a magnetic stirrer rotating 
at 50 rpm with the temperature of the buffer 
maintained at 37 ± 1 
0
C. One ml aliquot of the 
release medium (buffer) was withdrawn at 
time intervals of 1, 2, 4, 8, 16, 24 h and 
replaced with the same volume of PBS on 
each occasion. The withdrawn samples were 
filtered through 0.45 µm membrane filter 
(Elix, Mill-Q), diluted suitably and determined 
spectrophotometrically (model UV-1700, 
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In vivo drug distribution studies 
 
This study was performed to compare the 
targeting efficiency of the drug-loaded 
proniosomes with that of the plain drug in 
terms of degree of targeting to various organs 
of the reticuloendothelial system (RES), 
namely, liver, lung, spleen, kidney, heart and 
brain [16]. Nine healthy adult rats weighing 
200-250 g were selected and fasted for 12 h 
prior to the the test.  The animals were 
divided into 3 groups of 3 rats each. Group I 
received niosomes (batch F2) equivalent to 
810 mcg of irinotecan hydrochloride 
trihydrate intravenously in the tail vein after 
redispersing the niosomes in sterile PBS. 
Group-II rats received 810 mcg of pure (free) 
irinotecan hydrochloride trihydrate 
intravenously while Group-III rats were 
treated as vehicle control and injected 
intravenously with sterile PBS. All the animals 
of Group I and II were anaesthetized using 
Ketamine HCl (22mg/kg i.m) prior to 
administration of pure drug and formulation 
(F2) respectively
 
to reduce painful symptoms. 
 
The rats were sacrificed 3 h later by cervical 
dislocation
 
and their liver, lungs, spleen and 
kidneys isolated. The organs of each rat were 
homogenized separately in 5 mL ethanol 
using a tissue homogenizer (Remi Equipment 
Pvt Ltd, Mumbai, India) and the homogenate 
centrifuged at 15,000 rpm for 30 min. The 
supernatant was collected, filtered through a 
0.45 µ filter, and analyzed spectrophoto-
metrically at 369 nm after appropriate dilution 




The purpose of the stability testing was to 
determine the stability of the proniosomes 
over time under a variety of conditions, 
namely, temperature, humidity and light. The 
best batch of irinotecan-loaded proniosomes 
(F2) was used for test. All the preparations 
were divided into three sets and were stored 




in a refrigerator, ambient 
temperature and humidity (25 ± 2 °C/60 ± 5 
%RH), and 37 ± 2 ºC/65 ± 5 %RH in a 
humidity control oven (Lab Care, Mumbai, 
India). Three months later, drug content and 
in vitro drug release of the formulations were 





The data (mean ± standard deviation) were 
analyzed by Student’s t-test using Statistica 
for Windows (version 5.0, Statsoft, Inc, USA). 
Significant difference was set at a probability 




Morphology of dry proniosome powder 
 
Scanning electron microscopy of uncoated 
maltodextrin (Fig 1A) and dry proniosome 
powder (Fig 1B) reveals that there is a slight 
difference in the appearance of their 
surfaces. The powder in (Fig 1B) appears to 
be smoother indicating a thin and uniform 
coating over the maltodextrin powder. Also, 
based on the scale of the micrograph, no 
significant change in size of particles was 
seen. This shows that there is no aggregation 
of the particles due to surfactant coating. 
Furthermore, the scanning electron 
micrograph of the dried proniosome-derived 
niosome dispersions (Fig 1C) suggests that 
the niosomes generated from proniosomes 
were discrete and uniform.  
 
Angle of repose 
 
The angle of repose of the various 
formulations were 31.20 ± 0.75, 32.40 ± 1.62, 
31.70 ± 1.07 and 32.60 ± 2.04 for F1, F2, F3 
and F4, respectively. Angle of repose of pure 
maltodextrin was 32.8±1.87. The angle of 
repose data for the proniosome formulations 
and pure maltodextrin indicate that there no 
significant difference (p > 0.05) in their flow 
properties. This is, however, not consistent 
with the scanning electron microscopic 
findings for proniosomes, where it was 
observed that the proniosome surface was 
smoother.  
Goudanavar and Joshi  







Fig 1: Scanning electron micrograph of (A) 
maltodextrin powder (uncoated), (B) proniosomes 
(F2), and (C) niosomes derived from proniosomes 
 
 
Drug entrapment efficiency  
 
Table 1 shows the entrapment data. The 
entrapment efficiency of the proniosomal 
formulations ranged from 69.84±3.5% to 
74.94±2.7%for formulations F1 to F4. On the 
other hand, the entrapment efficiency of 
conventional niosomes was 61.17±3.5 which 
is statistically different due to the larger 
vesicle size of the latter. As the size of 
vesicle increased, surface area decreased 
leading also to decrease in drug entrapment.  
 
Table 1: Drug entrapment efficiency of irinotecan-
loaded proniosomes (mean ± SD, n = 3) 
 






Conventional niosomes 61.17±3.5 
 
In vitro drug release  
 
As Fig 2 indicates, cumulative drug release 
for F-1 to F-4 after 24 h was 96.33%, 95.88% 
, 98.16% and 97.38% , respectively. On the 
other hand, cumulative release of pure 
irinotecan in 5 h was 98.76 %. 
 
In vivo drug distribution 
 
Formulation F-2 with optimum particle size, 
and with good entrapment efficiency and in 
vitro release, was selected for the in vivo 
drug targeting studies. The distribution of the 
drug at the various organs following 
intravenous injection are shown in Fig 3. The 
mean distribution data, which are a measure 
of targeting efficiency of drug-loaded 
proniosomes, was 25.38% for liver, 9.64% in 
lungs, 9.26% in spleen, 5.7 % in 
kidney,7.69% in heart, and 21.62% in 
brain.whereas accumulation of pure drug was 
22.46% in liver, 8.86% in lungs, 9.68% in 
spleen, 11.14% in kidneys, 18.26% in heart 
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Fig 2: Cumulative drug release of proniosomal 
formulations and pure drug (◊ = F1, □ = F2, ∆ = 
F3, ○= F4, × = pure drug) 
 
 
Fig 3: Drug distribution (targeting efficiency) of 





The results of stability studies, shown in Fig 
4, indicate that angle of repose, entrapment 
efficience and drug release rate of the 
formulations did not change significantly 
(P>0.05) after storage under various 
conditions for 3 months, thus suggesting that 




Irinotecan is an effective anticancer agent 
and widely used in colon cancer therapy. 
However, its clinical use has been limited by 
dose-related side effects such as severe 
diarrhea and extreme suppression of the 
immune systems. Therefore, it is necessary 
to provide an alternative vesicular drug 
delivery system for irinotecan in the form of 
proniosomes which will have advantages of 
controlled drug release, site specificity, 
increased drug stability, high drug payload 




















Time (h)Fig 4: Cumulative drug release of F2 
formulation after 3 months following storage      
 at 4 
o





Preparation of the proniosomes on a 
maltodextrin carrier was relatively 
straightforward but it was necessary that the 
surfactant solution used be incorporated in 
very small amounts and that complete drying 
be ensured before further additions are 
made. As proniosomes are a dry powder, 
further processing is possible. Angle of 
repose data indicate that the fluidity of 
proniosome dry powder is equal to or better 
than that of maltodextrin powder; therefore, 
further processing of proniosome powder 
should not pose any problems. Hydration of 
the proniosome powder is much easier than 
the long shaking process required to hydrate 
surfactants in the conventional dry film 
method and this can be implemented in a 
‘point-of-use’ application.     
 
Drug entrapment efficiency studies revealed 
that the change in nonionic surfactant had a 
significant effect on entrapment of hydrophilic 
drug, Irinotecan hydrochloride trihydrate. 
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Entrapment efficiency of proniosomes 
composed of tweens was relatively low as 
compared to spans. Higher entrapment 
efficiency of vesicles of span 60 was 
predictable because of its higher alkyl chain 
length. A larger alkyl chain lowers the HLB 
value of a surfactant and this tends to 
increase entrapment efficiency of the drug. 
 
The in-vitro release of all the four batches of 
proniosomes showed bi-phasic release with 
an initial burst effect over the first hour. 
Thereafter, drug release followed a steady 
pattern approximating Higuchi matrix release. 
The burst release in the first hour can be 
attributed to the drug loaded on the surface of 
the vesicles as well as to the unentrapped 
drug in the niosomal suspension. The drug is 
adsorbed in the lipophilic region (between the 
bilayers) of the proniosomes where it may 
undergo rapid ionization and is released until 
equilibrium is reached [19]. Drug release was 
regulated by diffusion throughout the swollen 
niosomal membrane, after the initial burst 
release, with the remaining drug released 
over a period of 24 h. Cumulative drug 
release from F2 (containing Span 60) was 
lower than from other formulations  due to the 
higher alkyl chain length of the surfactant; the 
higher the chain length the slower the 
release. Drug release from the proniosome-
derived niosomes was far more controlled 
than from the conventional niosomes, and 
may therefore offer improved bioavailability of 
some poorly soluble drugs with poor 
solubility. 
 
The in vivo drug distribution results reveal 
that the drug loaded proniosomes showed 
preferential drug targeting to liver followed by 
brain, lungs, spleen, heart and kidneys. 
Compared to pure drug, higher 
concentrations of drug was targeted to the 
organs like liver after administering the dose 
in the form of proniosomes.Higher drug 
targeting to liver and brain is attributed to the 
increased lipophilicity of irinotecan loaded 
proniosomes.  
 
Stability studies of formulation F2 reveal that 
there was an overall increase in the drug 
release. These results may be attributed to 
phase transition of surfactant and lipid 
causing vesicles leakage to some extent 
during storage. From the stability data it can 
be concluded that 4º C is the most suitable 
condition for storage of irinotecan loaded 
proniosomes. 
 
Thus, by developing a dry proniosomal 
formulation, problems related to the 
hydrolysis of active ingredient or surfactants 
are eliminated. Since a suspension is formed, 
precipitation and aggregation are avoided. 
Maltodextrin-based proniosomes satisfied all 
these requirements thus indicating that 




The slurry method used is simple and 
suitable for laboratory-scale preparation of 
irinotecan proniosomes. Proniosomes offers 
an alternative colloidal carrier approach in 
achieving drug targeting as irinotecan 
proniosomes were retained at targeted sites 
and are capable of releasing there drug for 
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